Abbott Commences New Clinical Trial to Enhance Patient Outcomes in Advanced Heart Failure
Shots:
- Abbott will conduct TEAM-HF clinical evaluation aimed at improving patient outcomes in worsening heart failure needing advanced therapy options
- The TEAM-HF trial will use Abbott's CardioMEMS HF System to monitor pulmonary artery pressure (PAP) in heart failure patients. If PAP doesn't improve with standard therapy, patients will be randomized to receive either a HeartMate 3 LVAD implant or continue current medications. Patients whose PAP improves will join a registry for ongoing management with CardioMEMS data
- The study will recruit ~850 eligible patients with advanced heart failure patients who could benefit from early HeartMate 3 LVAD use in 75 global sites. 1 & 2EPs will be evaluated for 2yrs., with follow-up of 5yrs.
Ref: Abbott | Image: Abbott
Related News:- Abbott Reports the Study Advancements in Pulsed Field Ablation, Gets the US FDA’s Nod for Technology Supporting Cardiac Mapping
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
